Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

23andMe's genetics screening service sold in violation of regulations, says FDA

02 December 2013

By Ruth Saunders

Appeared in BioNews 733

The US Food and Drug Administration (FDA) has ordered 23andMe to 'immediately discontinue' its Personal Genome Service (PGS) after failing to undergo proper agency approval for its marketing claims.

Alberto Gutierrez, director of the FDA's Center for Devices and Radiological Health, stated in a letter dated 22 November, that 23andMe had failed to address the agency's concerns that the tests could dangerously mislead people about their health.

23andMe first introduced the PGS to the market in 2007, and sells access to an array of information on more than 260 genetic conditions and traits, from a person's carrier status, disease risk, drug response and traits.

The warning letter, addressed to 23andMe co-founder Anne Wojcicki, targeted specific marketing claims about the PGS as a 'first step in prevention' that enables users to 'take steps toward mitigating serious diseases', including heart disease, and breast cancer.

Gutierrez wrote that the 'FDA is concerned about the public health consequences of inaccurate results from the PGS device'.

He mentions 'the potential health consequences that could result from false positive or false negative assessments for high-risk indications such as these'.

'For instance, if the BRCA-related risk assessment for breast or ovarian cancer reports a false positive, it could lead a patient to undergo prophylactic surgery, chemoprevention, intensive screening, or other morbidity-inducing actions'.

Relying on the assessments for drug response could lead customers to 'self-manage' their treatment or abandon treatment altogether, resulting in illness, injury or death, according to the FDA.

The Federal Food, Drug and Cosmetics Act regulates products that are intended to diagnose, mitigate, treat or prevent disease.

The company must provide proof about how accurate its tests are as well as supplying information on the rate of false positives and false negatives.

'Most of these uses have not been classified and thus require premarket approval as FDA has explained to you on numerous occasions', said Gutierrez.

The FDA said it has had 'more than 14 face-to-face and teleconference meetings, hundreds of email exchanges, and dozens of written communications' with 23andMe to discuss compliance with the statute.

'The main purpose of compliance with FDA's regulatory requirements is to ensure that the tests work'.

'However, even after these many interactions with 23andMe, we still do not have any assurance that the firm has analytically or clinically validated the PGS for its intended uses, which have expanded from the uses that the firm identified in its submissions', Gutierrez wrote.

As such, the FDA writes that the applications are considered withdrawn and 23andMe must immediately discontinue marketing until it receives FDA authorisation for its claims.

Failure to take the proper action, the FDA warned, could lead to seizure, injunction, and civil money penalties.

23andMe co-founder Anne Wojcicki responded on the company's blog: 'In July 2012 23andMe submitted its first application for FDA clearance and followed on with another submission at the end of August'.

'We received feedback on those submissions and acknowledge that we are behind schedule with our responses'.

'This is new territory for both 23andMe and the FDA', she wrote.

SOURCES & REFERENCES
23andMe (press release) | 22 November 2013
 
US Food and Drug Administration | 22 November 2013
 
the 23andMe blog | 26 November 2013
 
23andMe Blog | 26 November 2013
 
BBC News | 26 November 2013
 
The Guardian | 25 November 2013
 
CBS News | 25 November 2013
 
Washington Post | 26 November 2013
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

16 November 2015 - by Lone Hørlyck 
The US Food and Drug Administration has sent warning letters to three gene-testing companies over the marketing and selling of what it claims are direct-to-consumer gene testing products without its approval...
05 May 2015 - by BioNews 
For the 800th issue of BioNews, we asked Anne Wojcicki eight questions about personal genomics company 23andMe...

23 February 2015 - by Alice Hazelton 
Genetic testing company 23andMe has obtained approval from the US Food and Drug Administration to market a direct-to-consumer genetic test for a rare mutation....
12 January 2015 - by Rebecca Carr 
23andMe, the personal genetics company, has announced an agreement with biotech company Genentech to identify new therapeutic targets for the treatment of Parkinson's disease...
08 December 2014 - by Arit Udoh 
US-based genetic testing company 23andMe has launched its controversial 'personal genome service' in the UK...

07 October 2013 - by Dr Sophie Pryor 
A US genetics company has been awarded a patent that relates to a DNA analysis service that predicts a baby's traits on the basis of its parents' genes....
20 May 2013 - by Dr James Heather 
The US medicines regulator, the Food and Drug Administration, has approved a genetic test to help doctors select suitable lung cancer patients to be treated with the drug erlotinib...
20 August 2012 - by Ruth Saunders 
23andMe, a US-based personal genomics company, has sought regulatory approval from the Food and Drug Administration for seven of its genetic tests....
31 May 2011 - by Dr Jay Stone 
A US company has launched a mail order genetic test that claims to provide 'athletes and parents of young sports competitors' with information about the user's athletic strengths, what type of training will be most beneficial, and potential injury risks...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation